Peroxisome proliferator-activated receptor 3D structures

3D Structures of PPAR3D Structures of PPAR

Updated on 21-September-2020

{"openlevels":0}

• PPARα
  • 1k7l – hPPARα LBD + G2409544 + NCOA1 - human
    
  • 3e94 – hPPARα LBD + fatty acid activator
    
  • 4bcr, 5hyk - hPPARα LBD + ligand
    
  • 1kkq – hPPARα LBD + GW6471 Antagonist + SMRT
    
  • 2npa - hPPARα LBD+ propanoic acid derivative + NCOA1
    
  • 2p54 - hPPARα LBD + NCOA1
    
  • 2rew - hPPARα LBD + azetidinone derivative activator
    
  • 2znn, 2zno, 2znp, 2znq, 3kdu, 3vi8, 1i7g, 4bcr, 5hyk - hPPARα LBD+ agonist
    
  • 3fei, 3fej, 3g8i, 3sp6 - hPPARα LBD+ agonist + NCOA1
    
  • 3et1 - hPPARα LBD + NCOA1 + indole derivative
• PPARγ
  • 3prg, 2qmv, 1prg – hPPARγ LBD
    
  • 6fzy, 6fzg - hPPARγ LBD (mutant)
    
  • 2zk0, 2zk1, 2zk2, 2zk3, 2zk4, 2zk5, 2zk6, 3vjh, 3vji, 4e4k, 4e4q, 4jl4, 5hzc, 4ci5, 4ci4, 6an1, 2f4b, 1zeo, 2ath, 2hwq, 2hwr, 2i4j, 2q59, 2q8s, 3b3k, 3bc5, 3cds, 3g9e, 3gbk, 3gz9, 3ia6, 3kdt, 3an3, 3an4, 3noa, 3r5n, 3r8a, 3vso, 3vsp, 2xkw, 3b0q, 3ho0, 3hod, 1knu, 1i7i, 1nyx, 2pob, 5azv, 6f2l, 6c5t, 6c5q, 5wr1, 5wr0, 5wqx, 6md2, 6md4, 6md1, 6md0, 6mcz, 6k0t, 6avi, 6aug – hPPARγ LBD + ligand
    
  • 4l98, 4l96 - hPPARγ LBD (mutant) + ligand
    
  • 3r8i - hPPARγ LBD + ureidofibrate derivative
    
  • 6o67, 6o68, 6dgr, 6dgq, 6dgo, 6dgl, 6d8x, 6c1i - hPPARγ LBD + agonist
    
  • 2g0h, 2g0g, 2i4p, 2i4z, 2q5g, 2q5p, 2q5s, 2q61, 2q6r, 3cdp, 3d6d, 4em9, 4ema, 4prg, 2q6s, 5f9b, 4yt1, 3wmh, 6d3e - hPPARγ LBD+ partial agonist
    
  • 2om9 - hPPARγ LBD + cannabinoid
    
  • 3b0r, 5lsg, 4r6s, 4r2u, 4r06, 6dh9, 6dcu, 6dbh - hPPARγ LBD + antagonist
    
  • 3osi, 3osw, 3pba - hPPARγ LBD + bisphenol derivative
    
  • 2p4y, 3adt, 3adu, 3adw, 3et3, 2hfp, 3ty0 - hPPARγ LBD + modulator
    
  • 2zvt - hPPARγ LBD (mutant) + modulator
    
  • 2vsr, 2vst, 2vv0, 2vv1, 2vv2, 2vv3, 2vv4, 3x1i, 3x1h, 3wj5, 3wj4, 3po9, 3sz1 - hPPARγ LBD + fatty acid activator
    
  • 3ads, 3adx, 5u5l, 4xum, 4xuh, 4xta, 4xld, 6d5a - hPPARγ LBD + anti-inflammatory drug
    
  • 4oj4 - hPPARγ LBD (mutant) + anti-inflammatory drug
    
  • 3adv - hPPARγ LBD + serotonin
    
  • 3k8s, 3et0, 2yfe, 4a4v, 4a4w, 4jaz, 5tto, 4pwl, 4pvu, 5y2t, 5y2o, 5ugm, 6dha - hPPARγ LBD + antidiabetic drug
    
  • 4o8f - hPPARγ LBD (mutant) + antidiabetic drug
    
  • 6enq - hPPARγ LBD + antifibrotic drug
    
• PPARγ complex with polypeptide
  • 1wm0 – hPPARγ LBD+ NCAO2 peptide + agonist
    
  • 5dwl, 5dvc, 5dv8, 5dv6, 5dv3, 5dsh - hPPARγ LBD+ NCOA2 peptide + inhibitor
    
  • 1zgy – hPPARγ LBD+ antidiabetic drug + nuclear receptor peptide
    
  • 2gtk, 3qt0, 5gtp, 5gto, 5gtn, 6jq7, 6izm, 6ilq, 6ijs, 6ijr, 6icj, 5ycp, 5ycn - hPPARγ LBD+ NCOA1 peptide
    
  • 3cs8, 3u9q- hPPARγ LBD + PGC-1A peptide
    
  • 3cwd - hPPARγ LBD + NCOA1-2 peptide
    
  • 5two, 6izn, 6fzp, 6fzj, 6fzf - hPPARγ LBD + modulating ligand
    
  • 3fur, 3kmg, 3v9t, 3v9v, 3v9y, 4f9m, 3b1m, 3lmp - hPPARγ LBD + SRC-1 peptide + modulator
    
  • 4fgy, 2prg - hPPARγ LBD + antidiabetic agent + NCOA1 peptide
    
  • 6ad9 - hPPARγ LBD + anticancer agent + NCOA1 peptide
    
  • 3s9s, 3t03, 2fvj- hPPARγ LBD + NCOA1 peptide + partial agonist
    
  • 4y29, 2fvj, 5azt - hPPARγ LBD + NCOA1 peptide + ligand
    
  • 3h0a - hPPARγ LBD + SRC 1 + retinoic acid receptor α + retinoic acid + partial agonist
    
  • 1k74, 1rdt, 1fm9 - hPPARγ LBD + NCOA1 + retinoic acid receptor α + retinoic acid + agonist
    
  • 5ji0 - hPPARγ LBD + retinoic acid receptor + NCOA1 peptide + antidiabetic drug
    
  • 3dzu, 3e00, 3dzy - hPPARγ LBD + DNA + retinoic acid receptor α + NCOA2 peptide + retinoic acid
    
  • 1fm6 - hPPARγ LBD + antidiabetic drug + retinoic acid receptor α + NCOA2 peptide + retinoic acid
    
  • 3vn2, 4hee, 4prg - hPPARγ LBD + NCOA1 peptide + activator
    
  • 6ms7 - hPPARγ LBD + PGC1 LXXLL
    
  • 6dgp, 5z6s, 5z5s - hPPARγ LBD + coactivator peptide
    
  • 6d94 - hPPARγ LBD + mediator of RNA polymerase II peptide
    
• PPARδ
  • 2gwx – hPPARδ LBD
    
  • 2env – hPPARδ zinc finger domain
    
  • 2baw, 2b50, 2awh – hPPARδ + Vaccenic Acid
    
  • 3gwx – hPPARδ LBD + 5,8,11,14,17-Eicosapentaenoic Acid
    
  • 3dy6 – hPPARδ LBD + anthranilic acid
    
  • 3et2, 1gwx – hPPARδ + fatty acid
    
  • 2j14, 2xyj, 2xyw, 2xyx, 3oz0, 3sp9, 5u3q, 5u3r, 5u3s, 5u3t, 5u3u, 5u3v, 5u3w, 5u3x, 5u3y, 5u3z, 5u40, 5u41, 5u42, 5u43, 5u44, 5u45, 1gwx, 3tkm, 1y0s, 5u46, 5y7x - hPPARδ LBD + agonist
    
  • 3peq - hPPARδ LBD + partial agonist
    
  • 3d5f - hPPARδ LBD + phenoxy derivative
    
  • 5xmx, 6a6p, 5zxi - hPPARδ LBD + inhibitor